Key result
Micro- and nanoparticles enable targeted therapeutic delivery for myocardial infarction and PAD.
Answers are grounded in this paper and cite their sources.
Cardiovascular disease, including myocardial infarction (MI) and peripheral artery disease (PAD), afflicts millions of people in Unites States. Current therapies are insufficient to restore blood flow and repair the injured heart or skeletal muscle, respectively, which is subjected to ischemic damage following vessel occlusion. Micro- and nano-particles are being designed as delivery vehicles for growth factors, enzymes and/or small molecules to provide a sustained therapeutic stimulus at the injured tissue. Depending on the formulation, the particles can be injected directly into the heart or skeletal muscle, or accumulate at the site of injury following an intravenous injection. In this article we review existing particle based therapies for treating MI and PAD.
No takes yet. Share an insight, caveat, or question.
Suarez et al. (2015) conducted a review in Cardiovascular disease, including myocardial infarction (MI) and peripheral artery disease (PAD). Micro- and nanoparticles as delivery vehicles for growth factors, enzymes, and/or small molecules was evaluated. Micro- and nanoparticles are reviewed as delivery vehicles for growth factors, enzymes, and small molecules to treat myocardial infarction and peripheral artery disease (no quantitative data reported).
Synapse has enriched 10 related papers. Consider them for comparative context: